Patents Examined by Tara L Martinez
  • Patent number: 10815272
    Abstract: The present invention provides peptides corresponding to fragments of CD31 that inhibit platelet and leukocyte activation, and to their use in the treatment of thrombotic disease. These peptides find use as therapeutic agents in the treatment of inflammatory diseases and thrombotic diseases such as atherothrombosis, in particular when immobilised onto solid supports.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: October 27, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, UNIVERSITE PARIS 13—PARIS NORD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Patent number: 10799442
    Abstract: Compounds of general formula (I): R1-Wm-Xn-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, and in processes of treatment and/or care of the skin, hair and/or mucous membranes, in particular in the aging and photoaging of the skin.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: October 13, 2020
    Assignee: LUBRIZOL ADVANCED MATERIALS, INC.
    Inventors: Nuria Alminana Domenech, Wim Van Den Nest, Maria Del Carmen Lidon, Antonio Ferrer Montiel
  • Patent number: 10772827
    Abstract: The present invention relates to a nasal administration composition for preventing or treating ischemic cerebrovascular disease, containing a Fas targeting peptide (FTP). When using the pharmaceutical composition or kit of the present invention, a drug can be effectively delivered to brain tissue and the ischemic cerebrovascular disease of a subject can be effectively prevented or treated.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: September 15, 2020
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Sang-Kyung Lee, Irfan Ullah, Kun Ho Chung, Jung Ju Oh, Min Hyung Lee, Priti Kumar
  • Patent number: 10775387
    Abstract: The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: September 15, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE PARIS, UNIVERSITE PARIS 13—PARIS NORD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Patent number: 10774122
    Abstract: The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 15, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Arul Chinnaiyan, Xiaoju Wang
  • Patent number: 10774111
    Abstract: The present invention relates to an opioid peptide represented by general formula TyrGlyGly-X1-X2-X3-X4, wherein: X1 is represented by Thr or Glu; X1 is represented by Gly or Thr or Ala; X3 is represented by Ala or Val or Gly or Glu; and X4 is represented by His or Gln or Thr or SEQ ID NO:1, or HisTyr or GlnTyr or ThrTyr. The invention also relates to pharmaceutical and food compositions comprising the peptide and to the use of the same for analgesic purposes, and/or for providing a feeling of satiety to a subject.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: September 15, 2020
    Assignees: EMBRAPA-EMPRESA BRASILEIRA DE PESQUISA AGROPECUARIA, FUNDAÇÃO UNIVERSIDADE DE BRASÍLIA—FUB—UNB
    Inventors: Carlos Bloch, Jr., Felipe Vinecky, Karla Graziella Moreira, Márcia Renata Mortari
  • Patent number: 10766927
    Abstract: Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis and uses thereof are provided.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: September 8, 2020
    Assignee: The Regents of the University of California
    Inventors: Eva A. Turley, Seyed Bahram Bahrami, Mina J. Bissell
  • Patent number: 10766946
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 8, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
  • Patent number: 10751390
    Abstract: Lipidated neuropeptides PrRP31, PrRP20, containing C14 to C16 fatty acid, and their analogs, wherein a sequence of IRPVGRF-NH2 at the C-terminus is variable in the site of isoleucine, valine and phenylalanine; said fatty acid is bound in position 1 or 11 for PrRP31 or its analog and in position 1 or 7 for PrRP20 or its analog; the bond comprises an amide bond between an amino acid having at least one free NH2 group and a carboxylic group of the fatty acid and alternatively includes also a binding through arm X2, which is a hydrophilic linker selected from a group comprising ?-alanine, ?-aminobutyric acid or ?-glutamic acid; for use in the treatment and prevention of diseases, which are Alzheimer's disease (AD), Parkinson's disease (PD), cognitive impairment no dementia (CIND), brain trauma, and neurodegenerative changes and disorders.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: August 25, 2020
    Assignee: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I.
    Inventors: Lenka Maletinska, Blanka Zelezna, Miroslava Blechova, Andrea Spolcova, Barbora Mikulaskova, Jaroslav Kunes, Stepan Strnad
  • Patent number: 10752657
    Abstract: A pharmaceutical composition comprising: (a) an isolated peptide, wherein the peptide includes three or four arginine-rich domains (ARDs) from the carboxy-terminal region of hepatitis B virus core protein (HBc) and exhibits an anti-microbial activity; and (b) a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 25, 2020
    Assignee: Academia Sinica
    Inventors: Chiaho Shih, Heng-Li Chen, Pei-Yi Su
  • Patent number: 10745440
    Abstract: The present invention pertains to peptides and peptide-containing complexes/nanoparticles that are useful for stabilizing and delivering cargo molecules such as nucleic acids.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 18, 2020
    Assignee: Aadigen, LLC
    Inventors: Gilles Divita, Neil Desai
  • Patent number: 10736941
    Abstract: The present invention addresses to provide a novel membrane permeability-improving agent which can be applied to high molecular drugs. More specifically, the present invention addresses to provide: a drug carrier which can improve the absorption efficiency of a high molecular drug in the small intestine; and a membrane permeation-improving agent containing the carrier. According to the present invention, a cell membrane-permeating peptide can be provided, which comprises an amino acid sequence selected from the group consisting of the following amino acid sequences: DNPGN (SEQ ID NO: 1); SRPAF (SEQ ID NO: 2); NDPRN (SEQ ID NO: 3); and MSVAN (SEQ ID NO: 4). According to the present invention, a cell membrane-permeable composition can also be provided, which comprises the peptide and a biologically active substance.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: August 11, 2020
    Assignee: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Shingo Ito, Sumio Ohtsuki
  • Patent number: 10738084
    Abstract: The invention relates to cyclic compounds of general formula (I): wherein R1, R2 and R3 are as defined in the specification, and their use as pharmaceuticals.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 11, 2020
    Assignee: Sentry Therapeutics Limited
    Inventors: Michael Peel, Andrew Scribner, Koichi Watashi, Satomi Shimura
  • Patent number: 10729748
    Abstract: Undue scarring of healing wounds is decreased and/or the relapse rate of wounds is lowered by applying a composition that includes hemoglobin to the wound area. At least 90% of the hemoglobin in the composition is provided in CO-charged form.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: August 4, 2020
    Assignee: MÖLNLYCKE HEALTH CARE AB
    Inventor: Michael Sander
  • Patent number: 10717772
    Abstract: New recombinant binding proteins, comprising designed ankyrin repeat domain(s) with binding specificity for HER2, and comprising designed ankyrin repeat domain(s) with binding specificity for serum albumin, are disclosed, as well as nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such recombinant binding proteins or nucleic acids and the use of such recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: July 21, 2020
    Assignee: Molecular Partners AG
    Inventors: Clara Metz, Ulrike Fiedler, Ignacio Dolado, Heike Maria Strobel
  • Patent number: 10711050
    Abstract: The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: July 14, 2020
    Assignee: ALBUMEDIX LTD
    Inventors: Michael March Schmidt, Eric Steven Furfine, Amy Jada Andreucci, Thomas M. Barnes
  • Patent number: 10703785
    Abstract: The invention provides structurally-constrained peptides by hydrocarbon stapling of a BCL9 HD2 helix for use as a therapeutic agent. The invention further provides methods and kits for use of the structurally-constrained peptide of the instant invention. The invention is based, at least in part, on the results provided herein demonstrating that hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, possess superior pharmacokinetic properties compared to the corresponding unmodified peptides, and are highly effective in binding to ?-catenin in vitro, in cellulo, and in vivo, disrupting the BCL-9/?-catenin interaction, and thereby interfering with deregulated Wnt/?-catenin signaling for therapeutic benefit in a variety of human diseases including human cancer.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: July 7, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Loren D. Walensky, Ruben Carrasco, Gregory H. Bird
  • Patent number: 10702574
    Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
    Type: Grant
    Filed: February 11, 2017
    Date of Patent: July 7, 2020
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Patent number: 10695407
    Abstract: The present invention relates to a protective solution for preventing or reducing reperfusion injury of the brain which contains magnesium ions and which has an osmolality of 350 to 600 mOsm/L, a pH value of 6.8 to 7.8 and albumin in an amount of 1 to 20% by weight.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: June 30, 2020
    Assignee: ResuSciTec GmbH
    Inventors: Christoph Benk, Friedhelm Beyersdorf, Georg Trummer
  • Patent number: 10689637
    Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: June 23, 2020
    Assignee: Wellstat ImmunoTherapeutics, LLC
    Inventors: ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang